The Radiation Therapy Oncology Group (RTOG) Community Clinical Oncology Program (CCOP) is unique in that it is the only CCOP focused solely on providing radiation (RT)-related symptom amelioration trials, as well as bringing state-of-the-art RT treatment trials to the CCOP community. The RTOG CCOP conducts trials that can only be accomplished in a RT specific group, such assessment of different fractionation schedules for the palliation of painful bone metastases, the use of stereotactic radiosurgery to palliate spinal metastases, and the use of hippocampal avoidance with RT treatment planning to minimize memory loss after whole brain RT for brain metastases. To meet our unique mission we have instituted significant strategic changes including new PI leadership;a lengthy evaluation of facilitators and barriers to concept development and patient accrual over the current grant period;a revised committee structure including a new Steering/Concept Review Committee to strengthen the science, increase our portfolio, and further engage the CCOPs and improve accrual. Objectives include: 1) provision of a cancer control research program to study interventions to prevent or manage symptoms, and the study of biological measures that will assist in earlier prediction of outcomes.
This aim i s focused on 4 research themes important to patients treated with RT: Protectants for Mucositis &Epithelial Injury;Neurocognition;Palliation &QoL;and Late Effects &Survivorship. 2) Provision of access to the full complement of clinical and translational protocols available through the RTOG to CCOP members, and 3) maintenance of an infrastructure and tools for conduct and assessment of the impact of RTOG cancer control studies. The CCOP has leveraged its NCI funding to help support these objectives by developing shared resources with the RTOG including a Translational Research Program, a Feasibility Review and Clinical Trials, Education and Recruitment Working Groups. Our past work, new vision and strategic changes will advance symptom management science and provide evidence for interventions that will ultimately improve the quality of survival for patients with cancer treated with RT.

Public Health Relevance

The unique goals of the Radiation Therapy Oncology Group's (RTOG) Community Clinical Oncology Program (CCOP) are to reduce the burden of illness and death related to cancer through treatment with radiation therapy (RT), and to prevent or reduce RT treatment related side effects. The RTOG CCOP goal is to provide evidence for interventions that will ultimately improve the quality of life for cancer survivors treated with RT.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA037422-26
Application #
8508189
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y (J1))
Program Officer
O'Mara, Ann M
Project Start
1994-06-01
Project End
2015-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
26
Fiscal Year
2013
Total Cost
$2,811,894
Indirect Cost
$1,297,516
Name
American College of Radiology
Department
Type
DUNS #
062485800
City
Reston
State
VA
Country
United States
Zip Code
20191
Lee, W Robert; Dignam, James J; Amin, Mahul B et al. (2016) Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol 34:2325-32
Li, Donghui; Moughan, Jennifer; Crane, Christopher et al. (2016) RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704. Int J Radiat Oncol Biol Phys 94:554-60
Voog, Justin C; Paulus, Rebecca; Shipley, William U et al. (2016) Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08. Eur Urol 69:204-10
White, Julia; Winter, Kathryn; Kuske, Robert R et al. (2016) Long-Term Cancer Outcomes From Study NRG Oncology/RTOG 9517: A Phase 2 Study of Accelerated Partial Breast Irradiation With Multicatheter Brachytherapy After Lumpectomy for Early-Stage Breast Cancer. Int J Radiat Oncol Biol Phys 95:1460-5
Divi, Vasu; Harris, Jonathan; Harari, Paul M et al. (2016) Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234). Cancer :
Small Jr, William; James, Jennifer L; Moore, Timothy D et al. (2016) Utility of the ACE Inhibitor Captopril in Mitigating Radiation-associated Pulmonary Toxicity in Lung Cancer: Results From NRG Oncology RTOG 0123. Am J Clin Oncol :
Buckner, Jan C; Shaw, Edward G; Pugh, Stephanie L et al. (2016) Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med 374:1344-55
Mitin, Timur; George, Asha; Zietman, Anthony L et al. (2016) Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233. Int J Radiat Oncol Biol Phys 94:67-74
Eaton, Bree R; Pugh, Stephanie L; Bradley, Jeffrey D et al. (2016) Institutional Enrollment and Survival Among NSCLC Patients Receiving Chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617. J Natl Cancer Inst 108:
Zhang, Qiang; Freidlin, Boris; Korn, Edward L et al. (2016) Comparison of futility monitoring guidelines using completed phase III oncology trials. Clin Trials :

Showing the most recent 10 out of 296 publications